Zepp Health Corporation
Revenue Dip, Cost-Cutting Success, Eyeing H2 Recovery
Published: 8/26/2024
Author: FRC Analysts
*See important disclosures at the bottom of this reportSector: Technology | Industry: Consumer Electronics
Ticker Symbols:
ZEPP - NYSE 🔹
- In Q2-2024, revenue was down 56% YoY, missing our estimate by 22% due to lower than anticipated unit sales. EBITDA remained negative, but improved due to higher gross margins, and lower operating expenses.
- Revenue declined due to the discontinuation of several low-margin products, with new product launches skewed toward H2-2024, combined with softer global demand for smartwatches, and stronger competition.
- Sources indicate that global smartwatch shipments declined by 9% YoY in Q2 amid slower global GDP growth. Additionally, average product pricing fell due to discounts driven by excess supply.